Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05372315 · ClinicalTrials.gov registry record · Phase 4

Efficacy of Dextenza Insert in Upper vs Lower Punctum Following Cataract Surgery With PCIOL.

A Phase 4 study of Cataract, sponsored by Iworks Laser and Vision Center.

Completed
Registry status
Phase 4
Development phase
80
Enrollment target
1
Study location

NCT05372315 is a Phase 4 study of Cataract that has completed, run by Iworks Laser and Vision Center. The registered enrollment target is 80 participants, below the 227-participant average among 83 other Cataract trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05372315, a Phase 4 study of Cataract, has completed, sponsored by Iworks Laser and Vision Center.

COMPLETED
Registry status
Phase 4
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

To assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) with or without iStent/Hydrus/Goniotomy when placed in the lower punctum compared to the upper punctum.

Conditions Studied

Interventions

  • DRUG Dextenza 0.4Mg Ophthalmic Insert

Study Locations (1)

Ohio

  • Iworks Laser & Vision Center - Dayton

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2022-06-15
Est. Completion 2022-10-31
Phase Phase 4

Sponsor

Iworks Laser and Vision Center

1 total trials

What the Registry Record Tells You About NCT05372315

The ClinicalTrials.gov registry entry for NCT05372315 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 227-participant average among 83 other Cataract trials with a reported enrollment target (65% lower). The listed sponsor is Iworks Laser and Vision Center, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 1 intervention - of which Dextenza 0.4Mg Ophthalmic Insert is the first listed.

NCT05372315 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05372315 about?

NCT05372315 is a clinical study titled "Efficacy of Dextenza Insert in Upper vs Lower Punctum Following Cataract Surgery With PCIOL.". To assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) with or without iStent/Hydrus/Goniotomy when placed in the lower punctum compared to the upper punctum.

What is the current status of trial NCT05372315?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2022-06-15. Estimated completion is 2022-10-31.

What conditions does trial NCT05372315 study?

This clinical trial studies the following conditions: Cataract.

What interventions are being tested in trial NCT05372315?

The interventions under investigation include: Dextenza 0.4Mg Ophthalmic Insert (DRUG).

Who is sponsoring clinical trial NCT05372315?

This trial is sponsored by Iworks Laser and Vision Center, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05372315 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.